CN113750139A - 一种从莲房中提取抗炎成分的方法及应用 - Google Patents
一种从莲房中提取抗炎成分的方法及应用 Download PDFInfo
- Publication number
- CN113750139A CN113750139A CN202111048567.2A CN202111048567A CN113750139A CN 113750139 A CN113750139 A CN 113750139A CN 202111048567 A CN202111048567 A CN 202111048567A CN 113750139 A CN113750139 A CN 113750139A
- Authority
- CN
- China
- Prior art keywords
- ethyl
- inflammatory
- elaeate
- solution
- lotus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000002853 Nelumbo nucifera Species 0.000 title claims abstract description 57
- 235000006508 Nelumbo nucifera Nutrition 0.000 title claims abstract description 57
- 235000006510 Nelumbo pentapetala Nutrition 0.000 title claims abstract description 55
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 90
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 75
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 59
- 239000003480 eluent Substances 0.000 claims abstract description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000178 monomer Substances 0.000 claims abstract description 27
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 21
- 230000002829 reductive effect Effects 0.000 claims abstract description 20
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 claims abstract description 19
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 claims abstract description 19
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims abstract description 19
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims abstract description 19
- 239000000706 filtrate Substances 0.000 claims abstract description 16
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims abstract description 15
- 102000043136 MAP kinase family Human genes 0.000 claims abstract description 14
- 108091054455 MAP kinase family Proteins 0.000 claims abstract description 14
- 229960002986 dinoprostone Drugs 0.000 claims abstract description 14
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 14
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims abstract description 14
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 239000000741 silica gel Substances 0.000 claims abstract description 12
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 12
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 10
- 238000004809 thin layer chromatography Methods 0.000 claims abstract description 10
- 229910021642 ultra pure water Inorganic materials 0.000 claims abstract description 9
- 239000012498 ultrapure water Substances 0.000 claims abstract description 9
- 238000001914 filtration Methods 0.000 claims abstract description 8
- 238000002791 soaking Methods 0.000 claims abstract description 8
- 238000010828 elution Methods 0.000 claims abstract description 7
- 238000000926 separation method Methods 0.000 claims abstract description 6
- 230000004913 activation Effects 0.000 claims abstract description 5
- 229940124599 anti-inflammatory drug Drugs 0.000 claims abstract description 5
- 238000012827 research and development Methods 0.000 claims abstract description 5
- 239000002893 slag Substances 0.000 claims abstract description 4
- 238000004458 analytical method Methods 0.000 claims abstract 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 18
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 18
- 239000002158 endotoxin Substances 0.000 claims description 18
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 18
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 15
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 claims description 13
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 claims description 13
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 claims description 13
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 claims description 13
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 claims description 13
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 9
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 9
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 9
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 claims description 9
- 229940031016 ethyl linoleate Drugs 0.000 claims description 9
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 9
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 claims description 9
- 235000005875 quercetin Nutrition 0.000 claims description 9
- 229960001285 quercetin Drugs 0.000 claims description 9
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 9
- 235000005493 rutin Nutrition 0.000 claims description 9
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 9
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 9
- 229960004555 rutoside Drugs 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000005481 NMR spectroscopy Methods 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 claims description 6
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims description 6
- RTATXGUCZHCSNG-TYSPDFDMSA-N Kaempferol-3-O-rutinoside Natural products OC1[C@H](O)[C@@H](O)C(C)O[C@H]1OCC1[C@@H](O)[C@@H](O)C(O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-TYSPDFDMSA-N 0.000 claims description 6
- RTATXGUCZHCSNG-QHWHWDPRSA-N Nicotiflorin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-QHWHWDPRSA-N 0.000 claims description 6
- 238000007664 blowing Methods 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 239000012452 mother liquor Substances 0.000 claims description 6
- RTATXGUCZHCSNG-ZFDPGQBLSA-N nicotiflorin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(c3ccc(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 RTATXGUCZHCSNG-ZFDPGQBLSA-N 0.000 claims description 6
- RTATXGUCZHCSNG-UHFFFAOYSA-N nicotiflorine Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-UHFFFAOYSA-N 0.000 claims description 6
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 3
- 244000062730 Melissa officinalis Species 0.000 claims description 2
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 238000004611 spectroscopical analysis Methods 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 102000003945 NF-kappa B Human genes 0.000 abstract description 8
- 108010057466 NF-kappa B Proteins 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 53
- 238000005516 engineering process Methods 0.000 description 19
- 238000001262 western blot Methods 0.000 description 12
- 239000009090 lianfang Substances 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical group S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000019491 signal transduction Effects 0.000 description 9
- LVGKNOAMLMIIKO-VAWYXSNFSA-N 9-Octadecenoic acid, ethyl ester Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-VAWYXSNFSA-N 0.000 description 8
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 8
- 102100040247 Tumor necrosis factor Human genes 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 6
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- -1 ethyl elaidic acid Chemical compound 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000010298 pulverizing process Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- XEYBRNLFEZDVAW-DODZYUBVSA-N 7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)CC(=O)[C@@H]1CC=CCCCC(O)=O XEYBRNLFEZDVAW-DODZYUBVSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 238000007605 air drying Methods 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 239000002024 ethyl acetate extract Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 230000025308 nuclear transport Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 230000006433 tumor necrosis factor production Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- ZENOXNGFMSCLLL-UHFFFAOYSA-N vanillyl alcohol Chemical compound COC1=CC(CO)=CC=C1O ZENOXNGFMSCLLL-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
- C07C67/56—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
- C07C67/58—Separation; Purification; Stabilisation; Use of additives by liquid-liquid treatment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/40—Separation, e.g. from natural material; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
- C07H17/065—Benzo[b]pyrans
- C07H17/07—Benzo[b]pyran-4-ones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
本发明属于天然产物化学领域,涉及一种从莲房中提取抗炎成分的方法,将干燥的莲房粉碎,用乙醇水溶液浸泡,碎渣过滤,滤液减压浓缩,并用超纯水分散,用乙酸乙酯萃取并浓缩,将浓缩液与硅胶混匀进行柱分离,用二氯甲烷和甲醇进行梯度洗脱,洗脱液进行薄层色谱分析,合并含有相同成分的洗脱液并浓缩,进行色谱鉴定,确定各成分的结构和纯度;对所得莲房单体成分进行抗炎作用分析,反油酸乙酯的抗炎能力最强,其可抑制炎症因子NO、PGE2和TNFα产生,降低iNOS和COX2的蛋白表达和mRNA水平,调节MAPKs和NF‑κB信号活化水平;本发明制得的反油酸乙酯纯度高,可作为抗炎药物研发的物质基础。
Description
技术领域
本发明属于天然产物化学领域,具体涉及一种从莲房中提取抗炎成分的方法及应用。
背景技术
炎症与人类健康密切相关,是自身免疫疾病、关节炎、肥胖、糖尿病和癌症等慢性疾病的关键风险因素。根据世界卫生组织的统计数据和报道,2018年全球癌症发生率为1810万、死亡率为960万;2016年超过6.5亿成人肥胖;2014年有4.22亿成人患有糖尿病。由此可见,开展抗炎研究对人民生命健康至关重要。尽管很多学者在抗炎研究中做出了巨大努力,但世界上许多人正在遭受炎症性疾病侵袭的现实表明,继续深入开展抗炎分子发现及其药理作用研究仍然具有重要的实际意义。
莲房又称为莲蓬,是睡莲科植物莲(Nelumbo nucifera Gaertn)的干燥成熟花托。中华人民共和国药典记载,莲房外观呈漏斗状或倒圆锥状,表面具有细纵纹和皱纹,顶面有多数圆形孔穴,基部有花梗残基。现代植物化学研究表明,莲房含有丰富的天然活性成分,包括生物碱、黄酮、萜类、有机酸、甾醇类、脂质、蛋白质以及碳水化合物等。并且药理学研究显示,莲房具有增强记忆、抑菌、抗炎、抗氧化、抗癌、防辐射和降血脂等多种功效。然而,由于莲房为非食用原料,常常在莲子加工过程中作为下脚料被废弃,导致其保健和药用价值未得到有效开发利用。
发明内容
本发明的目的在于提供一种从莲房中提取抗炎成分的方法,以莲房为原料,采用乙醇提取、减压浓缩、乙酸乙酯萃取、硅胶柱分离、二氯甲烷/甲醇洗脱和色谱鉴定等步骤制得了10个单体化合物,对所得莲房单体成分进行抗炎作用分析,反油酸乙酯(E9OAEE)的抗炎能力最强,可以抑制炎症因子NO、PGE2和TNFα产生,降低iNOS和COX2的蛋白表达和mRNA水平,调节MAPKs和NF-κB信号活化水平。本发明制得的反油酸乙酯纯度高,可作为抗炎药物研发的物质基础。
为实现上述目的,本发明采用如下技术方案:
一种从莲房中提取抗炎成分的方法,将干燥的莲房粉碎,用乙醇水溶液浸泡,碎渣过滤,滤液减压浓缩,并用超纯水分散,用乙酸乙酯萃取并浓缩,将浓缩液与硅胶混匀进行柱分离,用二氯甲烷和甲醇进行梯度洗脱,洗脱液进行薄层色谱分析,合并含有相同成分的洗脱液并浓缩,进行色谱鉴定,确定各成分的结构和纯度;对所得莲房单体成分进行抗炎作用分析,筛选出抗炎活性最高的单体成分。
进一步优选,莲房干物质与乙醇水溶液的质量体积比为1:15-20,乙醇水溶液的体积浓度为95%。
进一步优选,二氯甲烷和甲醇的梯度比例为100:1逐渐调整至1:1。
进一步优选,色谱鉴定技术主要包括核磁共振氢谱、质谱和高效液相色谱。
进一步优选,得到的10个莲房单体成分分别为异鼠李素-3-O-β-D-二葡萄糖苷、芦丁、槲皮素-3-O-β-D-半乳糖苷、山奈酚-3-O-芸香糖苷、槲皮素、亚油酸乙酯、反油酸乙酯、7β-羟基白桦酸、桦木酸、香树脂醇;用DMSO溶液将10个莲房单体成分充分溶解,使母液浓度为100mg/mL;调整RAW264.7细胞至对数生长期,并用新鲜培养液将细胞吹散、计数,调整细胞浓度,用多孔移液器将细胞均匀转移至96孔无菌培养板内,100μL/孔;24h后用无血清培养液将10个莲房单体成分配制成浓度为400μg/mL的待处理溶液,每个处理做3个复孔,每孔50μL,并做6个无药物的复孔,其中3个作为LPS对照,3个作为空白对照;2h后用无血清培养液配制浓度为4μg/mL的脂多糖溶液,每孔50μL,空白对照孔用无血清培养液代替;24h后用Griess试剂法检测细胞上清液中的NO含量,并评价各成分的抗炎能力,分析得出芦丁,槲皮素,亚油酸乙酯,反油酸乙酯,7β-羟基白桦酸和香树脂醇具有抗炎效果。
进一步优选,细胞浓度为5x10^5/mL-10x10^5/mL。
进一步优选,各莲房单体成分的终处理浓度为100μg/mL,LPS终处理浓度为1μg/mL。
进一步优选,10个莲房单体成分中,反油酸乙酯(E9OAEE)的抗炎能力最强,对NO产生的抑制率达到90%。
更特别的是,本发明提供了一种从莲房中提取抗炎成分反油酸乙酯的方法,将干燥的莲房粉碎,用乙醇水溶液浸泡,碎渣过滤,滤液减压浓缩,并用超纯水分散,用乙酸乙酯萃取并浓缩,将浓缩液与硅胶混匀进行柱分离,用二氯甲烷和甲醇进行梯度洗脱,控制洗脱液配比为二氯甲烷/甲醇=50/1,对洗脱液进行薄层色谱分析,合并含有相同成分的洗脱液并浓缩,得到反油酸乙酯。
本发明还提供了一种莲房抗炎成分-反油酸乙酯的应用,作为抗炎药物研发的基础物质。用于抑制炎症因子NO、PGE2和TNFα产生,降低iNOS和COX2的蛋白表达和mRNA水平,调节MAPKs和NF-κB信号活化水平。
本发明以莲房为原料,采用乙醇提取、减压浓缩、乙酸乙酯萃取、硅胶柱分离、二氯甲烷/甲醇洗脱和色谱鉴定等步骤制得了10个单体化合物。通过脂多糖诱导的RAW264.7细胞炎症模型,筛选到反油酸乙酯具有最显著的抗炎活性,其可以抑制炎症因子NO、PGE2和TNFα产生,降低iNOS和COX2的蛋白表达和mRNA水平,调节MAPKs和NF-κB信号活化水平。并且谱图数据显示,本发明制得的反油酸乙酯纯度高,抗炎效果较好,可作为抗炎药物研发的基础物质。
附图说明
图1本发明实施例1中10个莲房单体成分对NO含量影响的图谱;
图2本发明实施例1中系列浓度反油酸乙酯对NO含量(A)和细胞活力(B)影响的图谱;
图3本发明实施例1中系列浓度反油酸乙酯对PGE2(A)和TNFα(B)影响的图谱;
图4本发明实施例1中系列浓度反油酸乙酯对iNOS(A)和COX2(B)蛋白表达影响的图谱;
图5本发明实施例1中系列浓度反油酸乙酯对iNOS(A)、COX2(B)和GAPDH(C)mRNA水平影响的图谱;
图6本发明实施例1中系列浓度反油酸乙酯对MAPKs信号通路蛋白(ERK、P38和JNK)磷酸化水平影响的图谱;
图7本发明实施例1中系列浓度反油酸乙酯对NF-κB核转位影响的图谱。
具体实施方式
下面结合具体的实施例对本发明作进一步说明,所述的是对本发明的解释而不是限定。
实施例1
一种从莲房中提取抗炎成分的方法及应用:称取莲房干物质2kg,粉碎机粉碎,用15倍体积乙醇水溶液浸泡3天(72h),碎渣过滤,滤液用旋转蒸发器减压浓缩至约200mL,并重复此过程3次;用3倍体积的超纯水将浓缩液稀释分散,并用等体积乙酸乙酯对稀释液进行萃取,重复萃取3次至萃取相呈无色透明状,将乙酸乙酯萃取相进行减压浓缩至膏状,重量为4.225g;将膏状物与2倍量的硅胶混合均匀进行柱层析,用纯二氯甲烷作为洗脱液开始洗脱,后续以100:1的二氯甲烷/甲醇作为洗脱液再次洗脱,并不断提高洗脱液中甲醇的占比,即由100:1逐渐调整至1:1,将得到的洗脱液进行薄层色谱分析,显色剂为硫酸:甲醇(10:1),展开剂为二氯甲烷:甲醇(10:1),合并含有相同比移值成分的洗脱液,减压浓缩并室温晾干,利用核磁共振氢谱、质谱和高效液相色谱等技术确定化合物的结构和纯度。最终得到10个莲房单体成分,分别为异鼠李素-3-O-β-D-二葡萄糖苷、芦丁、槲皮素-3-O-β-D-半乳糖苷、山奈酚-3-O-芸香糖苷、槲皮素、亚油酸乙酯、反油酸乙酯、7β-羟基白桦酸、桦木酸、香树脂醇。
其中反油酸乙酯的提取过程为:将膏状物与2倍量的硅胶混合均匀进行柱层析,用二氯甲烷/甲醇=50/1的洗脱液进行洗脱,并进行薄层色谱分析,显色剂为硫酸:甲醇(10:1),展开剂为二氯甲烷:甲醇(10:1),合并含有相同比移值成分的洗脱液,减压浓缩并室温晾干,利用核磁共振氢谱、和质谱技术鉴定得到的产物为反油酸乙酯,经高效液相色谱技术分析所得反油酸乙酯的纯度达到98%。
用DMSO溶液将10种莲房单体成分充分溶解,使母液浓度为100mg/mL;调整RAW264.7细胞至对数生长期,并用新鲜培养液将细胞吹散、计数,使细胞浓度为5x10^5/mL,并用多孔移液器将细胞均匀转移至96孔无菌培养板内,100μL/孔;24h后用无血清培养液将10种莲房单体成分配制成浓度为400μg/mL的待处理溶液,每个处理做3个复孔,每孔50μL,并做6个无药物的复孔,其中3个作为LPS对照,3个作为空白对照;2h后用无血清培养液配制浓度为4μg/mL的脂多糖(LPS)溶液,每孔50μL,空白对照孔用无血清培养液代替;24h后用Griess试剂法检测细胞上清液中的NO含量,并评价各成分的抗炎能力。结果显示,芦丁,槲皮素,亚油酸乙酯,反油酸乙酯,7β-羟基白桦酸和香树脂醇具有抗炎效果,反油酸乙酯(E9OAEE)对NO产生的抑制效果最好,抑制率达到90%(图1)。
配制反油酸乙酯系列稀释浓度25、50、100、200和400μg/mL,通过Griess法检测各浓度反油酸乙酯对NO含量的影响,并通过MTT法检测反油酸乙酯的细胞毒性,通过ELISA技术检测反油酸乙酯对RAW264.7细胞炎症因子PGE2和TNF-α产生的影响,通过Westernbloting(WB)技术评价反油酸乙酯对炎症蛋白iNOS和COX2蛋白表达水平的影响;采用RT-PCR技术验证反油酸乙酯对炎症基因iNOS和COX2 mRNA水平的影响,通过WB和免疫荧光技术确认反油酸乙酯对MAPKs和NF-κB信号通路的影响。结果显示终浓度为6.25、12.5、25和50μg/mL的反油酸乙酯可以抑制NO产生,而且细胞毒性较小(图2)。反油酸乙酯可以抑制炎症因子PGE2和TNFα产生(图3),降低iNOS和COX2的蛋白表达(图4)和mRNA水平(图5),调节MAPKs信号通路蛋白ERK、P38和JNK的磷酸化水平(图6)和NF-κB转录因子的核转运(图7)。
实施例2
一种从莲房中提取抗炎成分的方法及应用:称取莲房干物质2kg,粉碎机粉碎,用15倍体积乙醇水溶液浸泡3天(72h),碎渣过滤,滤液用旋转蒸发器减压浓缩至约200mL,并重复此过程3次;用3倍体积的超纯水将浓缩液稀释分散,并用等体积乙酸乙酯对稀释液进行萃取,重复萃取3次至萃取相呈无色透明状,将乙酸乙酯萃取相进行减压浓缩至膏状,重量为4.10g;将膏状物与2倍量的硅胶混合均匀进行柱层析,用纯二氯甲烷作为洗脱液开始洗脱,后续以100:1的二氯甲烷/甲醇作为洗脱液再次洗脱,并不断提高洗脱液中甲醇的占比,即由100:1逐渐调整至1:1,将得到的洗脱液进行薄层色谱分析,显色剂为硫酸:甲醇(10:1),展开剂为二氯甲烷:甲醇(10:1),合并含有相同比移值成分的洗脱液,减压浓缩并室温晾干,利用核磁共振氢谱、质谱和高效液相色谱等技术确定化合物的结构和纯度。最终得到10个莲房单体成分,分别为异鼠李素-3-O-β-D-二葡萄糖苷、芦丁、槲皮素-3-O-β-D-半乳糖苷、山奈酚-3-O-芸香糖苷、槲皮素、亚油酸乙酯、反油酸乙酯、7β-羟基白桦酸、桦木酸、香树脂醇。
用DMSO溶液将10种莲房单体成分充分溶解,使母液浓度为100mg/mL;调整RAW264.7细胞至对数生长期,并用新鲜培养液将细胞吹散、计数,使细胞浓度为1x10^6/mL,并用多孔移液器将细胞均匀转移至96孔无菌培养板内,100μL/孔;24h后用无血清培养液将10种莲房单体成分配制成浓度为400μg/mL的待处理溶液,每个处理做3个复孔,每孔50μL,并做6个无药物的复孔,其中3个作为LPS对照,3个作为空白对照;2h后用无血清培养液配制浓度为4μg/mL的脂多糖(LPS)溶液,每孔50μL,空白对照孔用无血清培养液代替;24h后用Griess试剂法检测细胞上清液中的NO含量,并评价各成分的抗炎能力。结果显示反油酸乙酯(E9OAEE)对NO产生的抑制效果最好,抑制率达到90%(图1)。
配制反油酸乙酯系列稀释浓度25、50、100、200和400μg/mL,通过Griess法检测各浓度反油酸乙酯对NO含量的影响,并通过MTT法检测反油酸乙酯的细胞毒性,通过ELISA技术检测反油酸乙酯对RAW264.7细胞炎症因子PGE2和TNF-α产生的影响,通过Westernbloting(WB)技术评价反油酸乙酯对炎症蛋白iNOS和COX2蛋白表达水平的影响;采用RT-PCR技术验证反油酸乙酯对炎症基因iNOS和COX2 mRNA水平的影响,通过WB和免疫荧光技术确认反油酸乙酯对MAPKs和NF-κB信号通路的影响。结果显示终浓度为6.25、12.5、25和50μg/mL的反油酸乙酯可以抑制NO产生,而且细胞毒性较小(图2)。反油酸乙酯可以抑制炎症因子PGE2和TNFα产生(图3),降低iNOS和COX2的蛋白表达(图4)和mRNA水平(图5),调节MAPKs信号通路蛋白ERK、P38和JNK的磷酸化水平(图6)和NF-κB转录因子的核转运(图7)。
实施例3
一种从莲房中提取抗炎成分的方法及应用:称取莲房干物质2kg,粉碎机粉碎,用20倍体积乙醇水溶液浸泡3天(72h),碎渣过滤,滤液用旋转蒸发器减压浓缩至约200mL,并重复此过程3次;用3倍体积的超纯水将浓缩液稀释分散,并用等体积乙酸乙酯对稀释液进行萃取,重复萃取3次至萃取相呈无色透明状,将乙酸乙酯萃取相进行减压浓缩至膏状,重量为4.503g;将膏状物与2倍量的硅胶混合均匀进行柱层析,用纯二氯甲烷作为洗脱液开始洗脱,后续以100:1的二氯甲烷/甲醇作为洗脱液再次洗脱,并不断提高洗脱液中甲醇的占比,即由100:1逐渐调整至1:1,将得到的洗脱液进行薄层色谱分析,显色剂为硫酸:甲醇(10:1),展开剂为二氯甲烷:甲醇(10:1),合并含有相同比移值成分的洗脱液,减压浓缩并室温晾干,利用核磁共振氢谱、质谱和高效液相色谱等技术确定化合物的结构和纯度。最终得到10个莲房单体成分,分别为异鼠李素-3-O-β-D-二葡萄糖苷、芦丁、槲皮素-3-O-β-D-半乳糖苷、山奈酚-3-O-芸香糖苷、槲皮素、亚油酸乙酯、反油酸乙酯、7β-羟基白桦酸、桦木酸、香树脂醇。
用DMSO溶液将10种莲房单体成分充分溶解,使母液浓度为100mg/mL;调整RAW264.7细胞至对数生长期,并用新鲜培养液将细胞吹散、计数,使细胞浓度为5x10^5/mL,并用多孔移液器将细胞均匀转移至96孔无菌培养板内,100μL/孔;24h后用无血清培养液将10种莲房单体成分配制成浓度为400μg/mL的待处理溶液,每个处理做3个复孔,每孔50μL,并做6个无药物的复孔,其中3个作为LPS对照,3个作为空白对照;2h后用无血清培养液配制浓度为4μg/mL的脂多糖(LPS)溶液,每孔50μL,空白对照孔用无血清培养液代替;24h后用Griess试剂法检测细胞上清液中的NO含量,并评价各成分的抗炎能力。结果显示反油酸乙酯(E9OAEE)对NO产生的抑制效果最好,抑制率达到90%(图1)。
配制反油酸乙酯系列稀释浓度25、50、100、200和400μg/mL,通过Griess法检测各浓度反油酸乙酯对NO含量的影响,并通过MTT法检测反油酸乙酯的细胞毒性,通过ELISA技术检测反油酸乙酯对RAW264.7细胞炎症因子PGE2和TNF-α产生的影响,通过Westernbloting(WB)技术评价反油酸乙酯对炎症蛋白iNOS和COX2蛋白表达水平的影响;采用RT-PCR技术验证反油酸乙酯对炎症基因iNOS和COX2 mRNA水平的影响,通过WB和免疫荧光技术确认反油酸乙酯对MAPKs和NF-κB信号通路的影响。结果显示终浓度为6.25、12.5、25和50μg/mL的反油酸乙酯可以抑制NO产生,而且细胞毒性较小(图2)。反油酸乙酯可以抑制炎症因子PGE2和TNFα产生(图3),降低iNOS和COX2的蛋白表达(图4)和mRNA水平(图5),调节MAPKs信号通路蛋白ERK、P38和JNK的磷酸化水平(图6)和NF-κB转录因子的核转运(图7)。
实施例4
一种从莲房中提取抗炎成分的方法及应用:称取莲房干物质2kg,粉碎机粉碎,用20倍体积乙醇水溶液浸泡3天(72h),碎渣过滤,滤液用旋转蒸发器减压浓缩至约200mL,并重复此过程3次;用3倍体积的超纯水将浓缩液稀释分散,并用等体积乙酸乙酯对稀释液进行萃取,重复萃取3次至萃取相呈无色透明状,将乙酸乙酯萃取相进行减压浓缩至膏状,重量为4.776g;将膏状物与2倍量的硅胶混合均匀进行柱层析,用纯二氯甲烷作为洗脱液开始洗脱,后续以100:1的二氯甲烷/甲醇作为洗脱液再次洗脱,并不断提高洗脱液中甲醇的占比,即由100:1逐渐调整至1:1,将得到的洗脱液进行薄层色谱分析,显色剂为硫酸:甲醇(10:1),展开剂为二氯甲烷:甲醇(10:1),合并含有相同比移值成分的洗脱液,减压浓缩并室温晾干,利用核磁共振氢谱、质谱和高效液相色谱等技术确定化合物的结构和纯度。最终得到10个莲房单体成分,分别为异鼠李素-3-O-β-D-二葡萄糖苷、芦丁、槲皮素-3-O-β-D-半乳糖苷、山奈酚-3-O-芸香糖苷、槲皮素、亚油酸乙酯、反油酸乙酯、7β-羟基白桦酸、桦木酸、香树脂醇。
用DMSO溶液将10种莲房单体成分充分溶解,使母液浓度为100mg/mL;调整RAW264.7细胞至对数生长期,并用新鲜培养液将细胞吹散、计数,使细胞浓度为1x10^6/mL,并用多孔移液器将细胞均匀转移至96孔无菌培养板内,100μL/孔;24h后用无血清培养液将10种莲房单体成分配制成浓度为400μg/mL的待处理溶液,每个处理做3个复孔,每孔50μL,并做6个无药物的复孔,其中3个作为LPS对照,3个作为空白对照;2h后用无血清培养液配制浓度为4μg/mL的脂多糖(LPS)溶液,每孔50μL,空白对照孔用无血清培养液代替;24h后用Griess试剂法检测细胞上清液中的NO含量,并评价各成分的抗炎能力。结果显示反油酸乙酯(E9OAEE)对NO产生的抑制效果最好,抑制率达到90%(图1)。
配制反油酸乙酯系列稀释浓度25、50、100、200和400μg/mL,通过Griess法检测各浓度反油酸乙酯对NO含量的影响,并通过MTT法检测反油酸乙酯的细胞毒性,通过ELISA技术检测反油酸乙酯对RAW264.7细胞炎症因子PGE2和TNF-α产生的影响,通过Westernbloting(WB)技术评价反油酸乙酯对炎症蛋白iNOS和COX2蛋白表达水平的影响;采用RT-PCR技术验证反油酸乙酯对炎症基因iNOS和COX2 mRNA水平的影响,通过WB和免疫荧光技术确认反油酸乙酯对MAPKs和NF-κB信号通路的影响。结果显示终浓度为6.25、12.5、25和50μg/mL的反油酸乙酯可以抑制NO产生,而且细胞毒性较小(图2)。反油酸乙酯可以抑制炎症因子PGE2和TNFα产生(图3),降低iNOS和COX2的蛋白表达(图4)和mRNA水平(图5),调节MAPKs信号通路蛋白ERK、P38和JNK的磷酸化水平(图6)和NF-κB转录因子的核转运(图7)。
以上所揭露的仅为本发明一种较佳实施例而已,当然不能以此来限定本发明之权利范围,本领域普通技术人员可以理解实现上述实施例的全部或部分流程,并依本发明权利要求所作的等同变化,仍属于本发明所涵盖的范围。
Claims (8)
1.一种从莲房中提取抗炎成分的方法,其特征在于,将干燥的莲房粉碎,用乙醇水溶液浸泡,碎渣过滤,滤液减压浓缩,并用超纯水分散,用乙酸乙酯萃取并浓缩,将浓缩液与硅胶混匀进行柱分离,用二氯甲烷和甲醇进行梯度洗脱,洗脱液进行薄层色谱分析,合并含有相同成分的洗脱液并浓缩,进行色谱鉴定,确定各成分的结构和纯度;对所得莲房单体成分进行抗炎作用分析,筛选出抗炎活性最高的单体成分。
2.根据权利要求1所述的一种从莲房中提取抗炎成分的方法,其特征在于,莲房干物质与乙醇水溶液的质量体积比为1:15-20,乙醇水溶液的体积浓度为95%。
3.根据权利要求1所述的一种从莲房中提取抗炎成分的方法,其特征在于,二氯甲烷和甲醇的梯度比例为100:1逐渐调整至1:1。
4.根据权利要求1所述的一种从莲房中提取抗炎成分的方法,其特征在于,色谱鉴定技术主要包括核磁共振氢谱、质谱和高效液相色谱。
5.根据权利要求1所述的一种从莲房中提取抗炎成分的方法,其特征在于,得到的10个莲房单体成分分别为异鼠李素-3-O-β-D-二葡萄糖苷、芦丁、槲皮素-3-O-β-D-半乳糖苷、山奈酚-3-O-芸香糖苷、槲皮素、亚油酸乙酯、反油酸乙酯、7β-羟基白桦酸、桦木酸、香树脂醇;用DMSO溶液将10个莲房单体成分充分溶解,使母液浓度为100mg/mL;调整RAW264.7细胞至对数生长期,并用新鲜培养液将细胞吹散、计数,调整细胞浓度,用多孔移液器将细胞均匀转移至96孔无菌培养板内,100μL/孔;24h后用无血清培养液将10个莲房单体成分配制成浓度为400μg/mL的待处理溶液,每个处理做3个复孔,每孔50μL,并做6个无药物的复孔,其中3个作为LPS对照,3个作为空白对照;2h后用无血清培养液配制浓度为4μg/mL的脂多糖溶液,每孔50μL,空白对照孔用无血清培养液代替;24h后用Griess试剂法检测细胞上清液中的NO含量,并评价各成分的抗炎能力,分析得出芦丁,槲皮素,亚油酸乙酯,反油酸乙酯,7β-羟基白桦酸和香树脂醇具有抗炎效果。
6.一种从莲房中提取抗炎成分反油酸乙酯的方法,将干燥的莲房粉碎,用乙醇水溶液浸泡,碎渣过滤,滤液减压浓缩,并用超纯水分散,用乙酸乙酯萃取并浓缩,将浓缩液与硅胶混匀进行柱分离,用二氯甲烷和甲醇进行梯度洗脱,控制洗脱液配比为二氯甲烷/甲醇=50/1,对洗脱液进行薄层色谱分析,合并含有相同成分的洗脱液并浓缩,得到反油酸乙酯。
7.一种莲房抗炎成分反油酸乙酯的应用,其特征在于,作为抗炎药物研发的基础物质。
8.如权利要求7所述的莲房抗炎成分反油酸乙酯的应用,其特征在于,用于抑制炎症因子NO、PGE2和TNFα产生,降低iNOS和COX2的蛋白表达和mRNA水平,调节MAPKs和NF-κB信号活化水平。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111048567.2A CN113750139B (zh) | 2021-09-08 | 2021-09-08 | 一种从莲房中提取抗炎成分的方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111048567.2A CN113750139B (zh) | 2021-09-08 | 2021-09-08 | 一种从莲房中提取抗炎成分的方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113750139A true CN113750139A (zh) | 2021-12-07 |
CN113750139B CN113750139B (zh) | 2022-04-15 |
Family
ID=78793776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111048567.2A Active CN113750139B (zh) | 2021-09-08 | 2021-09-08 | 一种从莲房中提取抗炎成分的方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113750139B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115232187A (zh) * | 2022-08-10 | 2022-10-25 | 江西省科学院应用化学研究所 | 一种从龙脑樟中提取7β-羟基白桦脂酸的方法及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111110726A (zh) * | 2020-02-25 | 2020-05-08 | 福建中医药大学 | 一种莲房总黄酮的制备方法 |
WO2020235987A1 (en) * | 2019-05-17 | 2020-11-26 | Flora Solutions Sdn. Bhd. | Use of adenia cordifolia extract for wound healing |
CN112521441A (zh) * | 2020-12-29 | 2021-03-19 | 江西省科学院应用化学研究所 | 一种从莲蓬壳中分离纯化桦木酸的方法 |
-
2021
- 2021-09-08 CN CN202111048567.2A patent/CN113750139B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020235987A1 (en) * | 2019-05-17 | 2020-11-26 | Flora Solutions Sdn. Bhd. | Use of adenia cordifolia extract for wound healing |
CN111110726A (zh) * | 2020-02-25 | 2020-05-08 | 福建中医药大学 | 一种莲房总黄酮的制备方法 |
CN112521441A (zh) * | 2020-12-29 | 2021-03-19 | 江西省科学院应用化学研究所 | 一种从莲蓬壳中分离纯化桦木酸的方法 |
Non-Patent Citations (3)
Title |
---|
P. BALACHANDRAN,ET AL.: "Isolation of compounds from Sargassum wightii by GCMS and the molecular docking against anti-inflammatory marker COX2", 《INTERNATIONAL LETTERS OF CHEMISTRY, PHYSICS AND ASTRONOMY》 * |
宋静等: "莲房化学成分的分离鉴定", 《中国医药科学》 * |
李国群等: "莲房化学成分和生物活性研究进展", 《生物化工》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115232187A (zh) * | 2022-08-10 | 2022-10-25 | 江西省科学院应用化学研究所 | 一种从龙脑樟中提取7β-羟基白桦脂酸的方法及应用 |
CN115232187B (zh) * | 2022-08-10 | 2024-04-12 | 江西省科学院应用化学研究所 | 一种从龙脑樟中提取7β-羟基白桦脂酸的方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113750139B (zh) | 2022-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113750139B (zh) | 一种从莲房中提取抗炎成分的方法及应用 | |
CN101824067A (zh) | 玉蕊醇型三萜皂苷类化合物、制备方法及其应用 | |
Shu et al. | Identification and quantification of oleanane triterpenoid saponins and potential analgesic and anti-inflammatory activities from the roots and rhizomes of Panax stipuleanatus | |
Zhang et al. | Hierarchical extraction and simultaneous determination of flavones and triterpenes in different parts of Trichosanthes kirilowii Maxim. by ultra-high-performance liquid chromatography coupled with tandem mass spectrometry | |
CN108295102A (zh) | 一种具有降脂活性的辣木叶提取物及提取方法 | |
CN110452113A (zh) | 一种 (4→2)重排克罗烷型二萜类化合物及其制备方法和应用 | |
CN108101955B (zh) | 文冠果果壳中的化合物及其制备方法和用途 | |
CN115850218B (zh) | 一种乌药烷型倍半萜二聚体及其制备方法与应用 | |
CN112079804A (zh) | 一种山莴苣苦素及其作为抗炎成分的应用 | |
CN109010415B (zh) | 一种石油醚绿豆提取物及其制备方法和用途 | |
CN110403948A (zh) | 苯乙醇苷化合物在制备抗炎药物中的应用及其制备方法 | |
CN107880084A (zh) | 从凌霄属植物花中提取制备高纯度毛蕊花糖苷的方法 | |
CN110755476B (zh) | 一种紫苏叶中抗过敏成分的分离纯化方法 | |
CN110283055B (zh) | 一种化合物及其制备方法与用途 | |
CN108658770B (zh) | 一种从黑金刚马铃薯中制备绿原酸单体的方法 | |
CN107936001B (zh) | 芹菜素-8-C-β-D-木糖苷及其制备方法和应用 | |
CN114146104B (zh) | 一种土牛膝抗炎活性提取物 | |
CN106350545B (zh) | 一种芦蒿秸秆全组分利用的方法 | |
CN115368420B (zh) | 具有抗炎活性的化合物及其制备方法和应用 | |
CN112794812B (zh) | 从香蕉花中提取的生物碱类化合物及其提取方法 | |
CN110734449B (zh) | 胡芦巴中紫檀素类化合物及其制备方法和应用 | |
CN115286597B (zh) | 一种沙棘籽粕中5-羟色胺的分离制备方法及用途 | |
CN113307837B (zh) | 一种桦褐孔菌三萜类单体化合物的分离纯化方法及应用 | |
CN115716858B (zh) | 一种从油用牡丹籽粕中提取活性化合物β-谷甾醇的方法 | |
Chu et al. | Content determination of phenylpropanoids and enhancing exercise ability of effective fractions in pedicularis densispica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240109 Address after: 344200 C District, Chongren Industrial Park, Fuzhou, Jiangxi Patentee after: Chongren Hengkang Yisheng Camellia oleifera Technology Co.,Ltd. Patentee after: INSTITUTE OF APPLIED CHEMISTRY, JIANGXI ACADEMY OF SCIENCES Address before: No.7777, Changdong Avenue, high tech Development Zone, Nanchang City, Jiangxi Province, 330000 Patentee before: INSTITUTE OF APPLIED CHEMISTRY, JIANGXI ACADEMY OF SCIENCES |
|
TR01 | Transfer of patent right |